COURAGE patients who crossed branch.

This editorial comment was written by SOLACI.ORG and is based on an original article by Medscape which can be accessed free of charge at the bottom of this page.

COURAGE patients (Patients in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) who crossed from the optimal medical treatment branch to the revascularization branch within one year of randomization were more likely to present significant angina that affected their quality of life and were also more likely to be dissatisfied with the treatment and the health system in which they found themselves. These results were recently published in Circulation: Cardiovascular Quality and Outcomes.

No less important is the fact that crossing from optimal medical treatment to the revascularization branch was not associated with an increased risk of death or MI compared with patients who received early revascularization, although typically the symptoms and quality of life were worse in the optimal medical therapy group during that first year. With that information the author of the article, (Dr John Spertus), believes that we are better able to identify patients who require immediate revascularization which do not change hard end points. This is something that interventionists have argued for a long time. COURAGE has been criticized for allowing this crossover, (one third of the patients were crossed to follow up), and maybe this is the reason that no differences are observed in the hard end points. But critics say it is probable that critical patients are those who crossed within the first year, these were the ones that really could not be treated with medication only, the rest could be explained by the progression of the disease.

Of the 1,168 patients randomized to medical treatment, “only” 16% were crossed within the first year. The most important predictors of early revascularization were health status and the health system where they were assisted. For example, for patients treated in Canada were 37% more likely for early revascularization than those treated under the Veteran’s health system. Probably in the first system patients were more likely to express their symptoms and to make it clear to doctors that, despite optimal medical treatment, they were not satisfied and continued to feel limited.

This work does not have enough power to reach definitive conclusions but it seems clear that there are no differences in hard points such as death or myocardial infarction between the two strategies. However, we must be aware of the symptoms that patients report to provide adequate revascularization when (relatively common) medical treatment is not enough.

SOLACI.ORG

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...